Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash ...
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...
MedPage Today2d
Year in Review: Early Breast Cancer
News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...
Analytics India Magazine3d
AlphaFold 3 is Now Open Source—A New Era in Protein Prediction
In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...
TheHealthSite4d
What Are The Most Effective Treatments For Stage 4 Breast Cancer?
CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...